Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics

Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics

ES评分 0 浏览量：694 下载量：0

DOI	10.20900/jpbs.20210015
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2021, 6(4)
作者	Anissa Abi-Dargham*,
作者单位	Stony Brook University, 100 Nicolls rd, Stony Brook, 11794 NY, USA ;
Abstract	Multiple lines of evidence suggest a potential role for the kappa dynorphin system in schizophrenia and its therapeutics. Kappa stimulation acutely and chronically modulates dopamine in opposite ways, where acutely it decreases dopamine transmission and chronically it increases it and it can induce D2 sensitization. In addition, pharmacological evidence from studies using agonist and antagonists at KOR have indicated a therapeutic potential of KOR antagonists for psychosis. We present here a brief overview of the evidence supporting this viewpoint.
KeyWord	kappa opioid receptors; dynorphin; schizophrenia; antipsychotics
基金项目
页码	-

参考文献
相关文献

1.Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science. 1982;215(4531):413-5.

2.Clark SD, Abi-Dargham A. The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence. Biol Psychiatry. 2019;86(7):502-11.

3.Steiner H, Gerfen CR. Dynorphin regulates D1 dopamine receptor‐mediated responses in the striatum: Relative contributions of pre‐and postsynaptic mechanisms in dorsal and ventral striatum demonstrated by altered immediate‐early gene induction. J Comp Neurol. 1996;376(4):530-41.

4.Svingos AL, Chavkin C, Colago EE, Pickel VM. Major coexpression of κ‐opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse. 2001;42(3):185-92.

5.Escobar AP, González MP, Meza RC, Noches V, Henny P, Gysling K, et al. Mechanisms of kappa opioid receptor potentiation of dopamine D2 receptor function in quinpirole-induced locomotor sensitization in ratsKOR potentiation of D2R-induced behavior. Int J Neuropsychopharmacol. 2017 Aug 1;20(8):660-9.

6.Volavka J, Davis LG, Ehrlich YH. Endorphins, dopamine, and schizophrenia. Schizophr Bull. 1979;5(2):227-39.

7.Schmauss C, Emrich HM. Dopamine and the action of opiates: A reevaluation of the dopamine hypothesis of schizophrenia with special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia. Biol Psychiatry. 1985;20(11):1211-31.

8.Bruijnzeel AW. kappa-Opioid receptor signaling and brain reward function. Brain Res Rev. 2009;62(1):127-46.

9.Schwarzer C. 30 years of dynorphins—new insights on their functions in neuropsychiatric diseases. Pharmacol Ther. 2009;123(3):353-70.

10.Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther. 1988;244(3):1067-80.

11.Hawes SL, Salinas AG, Lovinger DM, Blackwell KT. Long‐term plasticity of corticostriatal synapses is modulated by pathway‐specific co‐release of opioids through κ‐opioid receptors. J Physiol. 2017;595(16):5637-52.

12.Tejeda HA, Wu J, Kornspun AR, Pignatelli M, Kashtelyan V, Krashes MJ, et al. Pathway-and cell-specific kappa-opioid receptor modulation of excitation-inhibition balance differentially gates D1 and D2 accumbens neuron activity. Neuron. 2017;93(1):147-63.

13.Manzanares J, Lookingland KJ, Moore KE. Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain. J Pharmacol Exp Ther. 1991;256(2):500-5.

14.Devine DP, Leone P, Pocock D, Wise R. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther. 1993;266(3):1236-46.

15.Maisonneuve I, Archer S, Glick S. U50, 488, a κ opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett. 1994;181(1-2):57-60.

16.Xi Z-X, Fuller SA, Stein EA. Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study. J Pharmacol Exp Ther. 1998;284(1):151-61.

17.Gray AM, Rawls SM, Shippenberg TS, McGinty JF. The K‐Opioid Agonist, U‐69593, Decreases Acute Amphetamine‐Evoked Behaviors and Calcium‐Dependent Dialysate Levels of Dopamine and Glutamate in the Ventral Striatum. J Neurochem. 1999;73(3):1066-74.

18.Chefer VI, Bäckman CM, Gigante ED, Shippenberg TS. Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacology. 2013;38(13):2623.

19.Zaratin P, Clarke GD. Comparative effects of selective κ-opioid receptor agonists on dopamine levels in the dorsal caudate of freely moving rats. Eur J Pharmacol. 1994;264(2):151-6.

20.Carlezon WA, Béguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, et al. Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther. 2006;316(1):440-7.

21.Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology. 2005;179(3):551-8.

22.Gehrke BJ, Chefer VI, Shippenberg TS. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology. 2008;197(3):509-17.

23.Fuentealba JA, Gysling K, Magendzo K, Andrés ME. Repeated administration of the selective kappa‐opioid receptor agonist U‐69593 increases stimulated dopamine extracellular levels in the rat nucleus accumbens. J Neurosci Res. 2006;84(2):450-9.

24.Fuentealba JA, Gysling K, Andrés ME. Increased locomotor response to amphetamine induced by the repeated administration of the selective kappa‐opioid receptor agonist U‐69593. Synapse. 2007;61(9):771-7.

25.del Pilar Escobar A, Cornejo FA, Andrés ME, Fuentealba JA. Repeated treatment with the kappa opioid receptor agonist U69593 reverses enhanced K (+) induced dopamine release in the nucleus accumbens, but not the expression of locomotor sensitization in amphetamine-sensitized rats. Neurochem Int. 2012 Mar;60(4):344-9.

26.Heidbreder CA, Schenk S, Partridge B, Shippenberg TS. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective κ‐opioid receptor agonist. Synapse. 1998;30(3):255-62.

27.Perreault ML, Graham D, Bisnaire L, Simms J, Hayton S, Szechtman H. Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre-and postsynaptic mechanisms. Neuropsychopharmacology. 2006;31(9):1967.

28.Perreault ML, Graham D, Scattolon S, Wang Y, Szechtman H, Foster JA. Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats. Psychopharmacology. 2007;194(4):485-96.

29.Perreault ML, Seeman P, Szechtman H. Kappa-opioid receptor stimulation quickens pathogenesis of compulsive checking in the quinpirole sensitization model of obsessive-compulsive disorder (OCD). Behav Neurosci. 2007;121(5):976.

30.Beerepoot P, Lam V, Luu A, Tsoi B, Siebert D, Szechtman H. Effects of salvinorin A on locomotor sensitization to D2/D3 dopamine agonist quinpirole. Neurosci Lett. 2008;446(2):101-4.

31.Acri JB, Thompson AC, Shippenberg T. Modulation of pre‐and postsynaptic dopamine D2 receptor function by the selective kappa‐opioid receptor agonist U69593. Synapse. 2001;39(4):343-50.

32.Collins SL, DʼAddario C, Izenwasser S. Effects of κ-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission. Eur J Pharmacol. 2001 Aug 24;426(1-2):25-34.

33.Collins S, Gerdes R, DʼAddario C, Izenwasser S. Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity. Behav Pharmacol. 2001 Jul;12(4):237-45.

34.Shippenberg T, Chefer V, Zapata A, Heidbreder CJAotNYAoS. Modulation of the behavioral and neurochemical effects of psychostimulants by κ‐opioid receptor systems. Ann N Y Acad Sci. 2001 Jun;937:50-73.

35.Ehrich JM, Phillips PE, Chavkin C. Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse nucleus accumbens. Neuropsychopharmacology. 2014;39(13):3036.

36.Chartoff EH, Ebner SR, Sparrow A, Potter D, Baker PM, Ragozzino ME, et al. Relative timing between kappa opioid receptor activation and cocaine determines the impact on reward and dopamine release. Neuropsychopharmacology. 2016;41(4):989.

37.Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A. Pathway-Specific Dopamine Abnormalities in Schizophrenia. Biol Psychiatry. 2017;81(1):31-42.

38.Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR, et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry. 2013 Aug;18(8):909-15.

39.Clark SD, Van Snellenberg JX, Lawson JM, Abi-Dargham A. Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials. Neuropsychopharmacology. 2020;45(11):1860-9.

40.Tejeda HA, Wang H, Flores RJ, Yarur HE. Dynorphin/Kappa-Opioid Receptor System Modulation of Cortical Circuitry. Handb Exp Pharmacol. 2021 Feb 13. doi: 10.1007/164_2021_440

41.Resnick RB, Fink M, Freedman AM. Cyclazocine treatment of opiate dependence: A progress report. Compr psychiatry. 1971;12(6):491-502.

42.Hanlon TE, McCabe OL, Savage C, Kurland AA. A controlled comparison of cyclazocine and naloxone treatment of the paroled narcotic addict. Int pharmacopsychiatry. 1975;10:240-50.

43.Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther. 1986;238(3):960-8.

44.Watson SJ, Berger PA, Akil H, Mills MJ, Barchas JD. Effects of naloxone on schizophrenia: Reduction in hallucinations in a subpopulation of subjects. Science. 1978;201(4350):73-6.

45.Jasinski DR, Martin WR, Sapira JD. Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. Clin Pharmacol Ther. 1968;9(2):215-22.

46.Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by k opiate receptors. Science. 1986;233(4765):774-6.

47.Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R, Rajagopalan R. Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa‐opioid agonist (CI‐977) in humans. J Clin Pharmacol. 1994;34(11):1126-32.

48.Giuffra M, Mouradian M, Davis T, Ownby J, Chase T. Dynorphin agonist therapy of Parkinsonʼs disease. Clin neuropharmacol. 1993;16(5):444-7.

49.Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, et al. Aquaretic effects of niravoline, a κ-opioid agonist, in patients with cirrhosis. J Hepatol. 2000;32(1):38-42.

50.Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology. 2001;157(2):151-62.

51.Wadenberg ML. A Review of the Properties of Spiradoline: A Potent and Selective k‐Opioid Receptor Agonist. CNS Drug Rev. 2003;9(2):187-98.

52.Dortch-Carnes J, Potter DE. Bremazocine: A κ-Opioid Agonist with Potent Analgesic and Other Pharmacologic Properties. CNS Drug Rev. 2005;11(2):195-212.

53.Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, et al. Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci U S A. 2002;99(18):11934-9.

54.Addy PH. Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology. 2012;220(1):195-204.

55.MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology. 2013;226(2):381-92.

56.Maqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, et al. Naltrexone but not ketanserin antagonizes the subjective, cardiovascular, and neuroendocrine effects of salvinorin-A in humans. Int J Neuropsychopharmacol. 2016;19(7):pyw016.

57.Emrich H, Cording C, Piree S, Kölling A, Zerssen D, Herz A. Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmacopsychiatry. 1977;10(05):265-70.

58.Lehmann HE, Cooper TH, Nair NPV, Kline NS. Beta-Endorphins and Naloxone in Psychiatric Patients: Clinical and Biological Effects. Am J Psychiatry. 1979 Jun;136(6):762-6.

59.Berger P, Watson S, Akil H, Barchas J. The effects of naloxone in chronic schizophrenia. Am J Psychiatry. 1981;138(7):913-8.

60.Emrich H, Höllt V, Laspe H, Fischler M, Heinemann H, Kissling W, et al. Studies on a possible pathological significance of endorphins in psychiatric disorders. Neuropsychopharmacology. 1979:527-34.

61.Kleinman JE, Weinberger DR, Rogol A, Shiling DJ, Mendelson WB, Davis GC, et al. Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects. Psychiatry Res. 1982;7(1):1-7.

62.Cohen MR, Pickar D, Cohen RM. High-dose naloxone administration in chronic schizophrenia. Biol psychiatry. 1985;20(5):573-5.

63.Pickar D, Vartanian F, Bunney WE, Maier HP, Gastpar MT, Prakash R, et al. Short-term naloxone administration in schizophrenic and manic patients: A World Health Organization collaborative study. Arch Gen Psychiatry. 1982;39(3):313-9.

64.Naber D, Münch U, Wissmann J, Grosse R, Ritt R, Welter D. Naloxone treatment for five days ineffective in schizophrenia. Acta Psychiatr Scand. 1983;67(4):265-71.

65.Emrich H, Bergmann M, Kissling W, Schmid W, Zerssen D, Costa AHE, et al. Neural Peptides and Neuronal Communication. New York (US): Raven Press; 1980.

66.Sethi BB, Prakash R. A study of naloxone with schizophrenic and manic patients. Br J Psychiatry. 1981;138(6):501-3.

67.Naber D, Leibl K. Repeated high dosage naloxone treatment without therapeutic efficacy in schizophrenic patients. Pharmacopsychiatry. 1983;16(02):43-5.

68.Verhoeven WM, Van Praag HM, Van Ree JM. Repeated naloxone administration in schizophrenia. Psychiatry Res. 1984;12(4):297-312.

69.Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30(4):490-6.

70.Pickar D, Bunney W, Douillet P, Sethi B, Sharma M, Vartanian M, et al. Repeated naloxone administration in schizophrenia: a phase II World Health Organization study. Biol psychiatry. 1989;25(4):440-8.

71.Vijay A, Morris E, Goldberg A, Petrulli J, Liu H, Huang Y, et al. Naltrexone occupancy at kappa opioid receptors investigated in alcoholics by PET occupancy at kappa opioid receptors investigated in alcoholics by PET. J Nucl Med. 2017;58(suppl 1):1297.

72.Marchesi G, Santone G, Cotani P, Giordano A, Chelli F. Naltrexone in chronic negative schizophrenia. Clin Neuropharmacol. 1992;15(Part A):56A-7.

73.Marchesi GF, Santone G, Cotani P, Giordano A, Chelli F. The therapeutic role of naltrexone in negative symptom schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 1995;19(8):1239-49.

74.Tatari F, Shakeri J, Farnia V, Hashemian A, Rezaei M, Abdoli N. Naltrexone Augmentation of Risperidone in Treatment of Schizophrenia Symptoms: a Randomized Placebo-Controlled Study. Ann Psychiatry Ment Health 2014;2(3):1016.

75.Mielke DH, Gallant DM. An oral opiate antagonist in chronic schizophrenia: a pilot study. Am J psychiatry. 1977 Dec;134(12):1430-1.

76.Simpson G, Branchey M, Lee J. Trial of Naltrexone in Chronic-schizophrenia. Curr Ther Res. 1977;22(6):909-13.

77.Ragheb M, Berney S, Ban T. Naltrexone in chronic schizophrenia. Int Pharmacopsychiatry. 1980;15:1-5.

78.Gitlin MJ, Gerner RH, Rosenblatt M. Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacology. 1981;74(1):51-3.

79.Sernyak MJ, Glazer WM, Heninger GR, Charney DS, Woods SW, Petrakis IL, et al. Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol. 1998;18(3):248-51.

80.Schmauss C, Yassouridis A, Emrich HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987;144(10):1340-2.

81.Groves S, Nutt DJ. Buprenorphine and schizophrenia. Human Psychopharmacol. 1991;6(1), 71-2.

82.Rapaport MH, Wolkowitz O, Kelsoe JR, Pato C, Konicki PE, Pickar D. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. Neuropsychopharmacology. 1993;9(2):111-5.

83.Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, et al. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018;18(1):82-4.

84.Li S, Cai Z, Zheng MQ, Holden D, Naganawa M, Lin SF, et al. Novel (18)F-Labeled kappa-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of (18)F-LY2459989 in Nonhuman Primates. J Nucl Med. 2018;59(1):140-6.

85.Zheng MQ, Kim SJ, Holden D, Lin SF, Need A, Rash K, et al. An Improved Antagonist Radiotracer for the kappa-Opioid Receptor: Synthesis and Characterization of (11)C-LY2459989. J Nucl Med. 2014;55(7):1185-91.

引用本文

Anissa Abi-Dargham*. Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics, Journal of Psychiatry and Brain Science. 2021; 6; (4). https://doi.org/10.20900/jpbs.20210015.

文献评论

相关学者

相关机构